<DOC>
	<DOCNO>NCT00003382</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy consist gemcitabine topotecan treating patient refractory recurrent ovarian fallopian tube cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Consisting Gemcitabine And Topotecan Treating Patients With Refractory Recurrent Ovarian Fallopian Tube Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerated dos combination gemcitabine topotecan administer without filgrastim ( G-CSF ) patient refractory ovarian fallopian tube cancer . - Describe quantitate clinical toxicity regimens patient population . OUTLINE : This dose escalation study . Patients receive gemcitabine IV 30 minute day 1 8 topotecan IV 30 minute day 2-4 . Some patient receive filgrastim ( G-CSF ) subcutaneously day 9-14 . Treatment repeat every 28 day 5-10 course . Cohorts 3-6 patient receive escalate dos topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose limit toxicity ( DLT ) . Dose escalation gemcitabine continue cohort 3-6 patient MTD determine . The MTD define dose 2 6 patient experience DLT . Patients follow every 2-3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 24 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document refractory recurrent ovarian epithelial fallopian tube cancer No borderline ovarian cancer Extraovarian papillary serous tumor eligible Must eligible high priority phase II III GOG protocol PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : SGOT great 3 time upper limit normal ( ULN ) Bilirubin great 1.5 mg/dL Elevated level alkaline phosphatase allow Renal : Creatinine great 1.5 mg/dL Cardiovascular : No angina pectoris clinically significant multifocal uncontrolled cardiac dysrhythmias No uncontrolled hypertension Other : No active malignancy No prior malignancy within past 5 year except nonmelanomatous skin cancer No active infection No underlying medical problem would prevent compliance No known hypersensitivity E. coliderived drug preparation Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Must receive least 1 prior platinum paclitaxelbased regimen At least 4 week since prior chemotherapy No prior topotecan and/or gemcitabine No prior chemotherapy different prior malignancy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy 10 % bone marrow At least 2 week since limited field radiation therapy Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>